Article
The FDA has granted approval to two generic versions of extended-release oxybutynin chloride for the treatment of overactive bladder.
The FDA has granted approval to two generic versions of extended-release oxybutynin chloride for the treatment of overactive bladder. Mylan Laboratories received final approval for 5- and 10-mg extended-release tablets, and IMPAX Laboratories received approval for 15-mg extended-release tablets. Both companies said the products would be launched immediately.
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.